Onye na-achọ ọgwụ ọhụrụ maka ọrịa nje na-eguzogide Carbapenem

0 nzuzu 3 | eTurboNews | eTN

Sumitovant Biopharma Ltd., na mmekorita ya na ụlọ ọrụ nne na nna Sumitomo Dainippon Pharma Co., Ltd., kwupụtara n'oge na-adịbeghị anya mmalite nke usoro ọmụmụ nke 1 na US maka onye nyocha ọgwụ ọhụrụ ("KSP-1007") maka ọrịa nje na-eguzogide carbapenem. . Mwepụta a sitere na ọrụ nyocha ọnụ n'etiti Sumitomo Dainippon Pharma na Kitasato Institute na Japan. Sumitovant na-eduzi mmemme nke ogige dị na US na-elekwasị anya na tract urinary mgbagwoju anya na ọrịa intra-abdominal.            

Myrtle Potter, onye isi ndị isi Sumitovant kwuru, "Enwere nnukwu mkpa ahụike na-egbobeghị maka ọgwụgwọ dị irè nke ọrịa ndị gbagwojuru anya n'ofe ụwa." "Ịzụlite usoro ọgwụgwọ nje bacteria adịbeghị mkpa ma ọ bụ ngwa ngwa. Ekwenyere m na onye nyocha ọgwụ a nwere ike ịbụ nhọrọ ọgwụgwọ dị irè megide ọrịa nje na-eguzogide carbapenem nke na-emetụta ọtụtụ ndị nọ na US na karịa. "

Ọrịa urinary tract so na ihe na-ebutekarị sepsis. Ọrịa gbagwojuru anya bụ ndị nwere nnukwu ihe ize ndụ nke ọdịda ọgwụgwọ yana na-achọkarị usoro ọmụmụ ọgwụ nje ogologo oge. Ọrịa intra-abdominal gbagwojuru anya bụ ọrịa na-efe efe na-agafe mgbidi nke oghere oghere nke sitere n'ime oghere afọ mgbe ejikọtara ya na abscess ma ọ bụ peritonitis.

"Ọ na-egosi site na data na-abụghị nke ahụike na KSP-1007 na-egbochi ma na-egbochi β-lactamases, nke bụ enzymes nke nje bacteria na-emepụta nke nwere ike imebi ọgwụ nje carbapenem," Salomon Azoulay, MD Chief Medical Officer na Head of Research & Development na Sumitovant kwuru. Onye otu ya na-eduzi nhazi na igbu nke usoro ọmụmụ nke 1 na US "Anyị na-amụ KSP-1007 na meropenem hydrate, ọgwụ nje carbapenem, nke a na-ejikarị agwọ ọrịa Gram (-), iji kwalite nrụpụta ọrụ na mgbagwoju anya. ọrịa urinary tract na intra-abdominal ọrịa.

Mmepe ọgwụ nje ọhụrụ bụ okwu mba ụwa dị ngwa ngwa. Mwepụta na mgbasa nke nje bacteria na-eguzogide ọgwụ nje (AMR), bụ nke na-eguzogide ọgwụ nje, bụ nsogbu na nchegbu zuru ụwa ọnụ na-eto eto. Ụlọ akụ ụwa na-eme atụmatụ na mmadụ 700,000 na-anwụ n'ihi nje nje nje AMR kwa afọ.1 Òtù Ahụ Ike Ụwa na-akpọ oku ka e mee ihe ngwa ngwa ma n'ọkwa mba na n'ụwa nile iji lụso ọrịa ndị a ọgụ na ịzụlite ọgwụgwọ ọhụrụ. N'ihi mmụba nke ojiji ọgwụ nje ndị metụtara COVID-19, enwere nchegbu na nje bacteria na-eguzogide ọgwụ ga-agbasa ọbụna n'ihu.

Sumitovant na Sumitomo Dainippon Pharma kpebisiri ike ịchọta nhọrọ ọgwụgwọ ọhụụ maka ọgwụgwọ na ọnọdụ kacha sie ike n'ofe ụwa. Ịmepụta ọgwụgwọ nje nje ọhụrụ bụ otu ebe a na-elekwasị anya maka ndị nyocha ụlọ ọrụ.

IHE Ị GA-Ewepụ na edemede a:

  • Ekwenyere m na onye nyocha ọgwụ a nwere ike ịbụ nhọrọ ọgwụgwọ dị irè megide ọrịa nje na-eguzogide carbapenem nke na-emetụta ọtụtụ ndị nọ na U.
  • Ọrịa intra-abdominal gbagwojuru anya bụ ọrịa na-efe efe na-agafe mgbidi nke oghere oghere nke sitere n'ime oghere afọ mgbe ejikọtara ya na abscess ma ọ bụ peritonitis.
  • Mwepụta a sitere na ọrụ nyocha ọnụ n'etiti Sumitomo Dainippon Pharma na Kitasato Institute na Japan.

<

Banyere chepụtara

Linda Hohnholz

Onye nchịkọta akụkọ maka eTurboNews dabere na eTN HQ.

Idenye aha
Gwa nke
guest
0 Comments
Inline nzaghachi
Lee echiche niile
0
Ga-ahụ n'anya gị echiche, biko okwu.x
Kekọrịta ka...